Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
49 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2018
ObjectiveOne objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long‐term rates of organ damage. We undertook this study to analyze data from a large clinical SLE cohort to compare patients achieving different levels of disease activity with respect to rates of long‐term damage.MethodsWe analyzed data from 1,356 SLE patients in the Hopkins Lupus Cohort, followed up quarterly, with 77,105 person‐months observed from 1987 to 2016. Three outcome measures were considered: clinical remission with no treatment, clinical remission on treatment, and lupus low disease activity state (LLDAS).ResultsPatients achieved LLDAS in 50% of their follow‐up months. They achieved clinical remission with no treatment or clinical remission on treatment in only 13% and 27%, respectively, of their follow‐up visits. The rates of damage consistently declined with increased percentage of prior time in either LLDAS or clinical remission on treatment. Spending a short proportion of prior time (<25%) in clinical remission on treatment was associated with a relatively low rate of damage compared to never achieving that condition (1.01 events per 10 person‐years versus 1.82 events per 10 person‐years; rate ratio 0.54, P < 0.0001). Those patients who experienced LLDAS at least 50% of the time had relatively low rates of damage (rate ratio 0.39–0.47, P < 0.0001).ConclusionLLDAS is an easier target to achieve than clinical remission on treatment and results in reduced risk of long‐term damage. However, even a small percentage of time in clinical remission on treatment was associated with reduced damage.
Arthritis & rheumatology (Hoboken, N.J.) · 2020
ObjectiveIn 2016, the American Academy of Ophthalmology (AAO) changed the recommended daily dose of hydroxychloroquine (HCQ) from 6.5 mg/kg to <5 mg/kg. However, it is not clear that the lower prescribed dose of HCQ will have the same efficacy for systemic lupus erythematosus (SLE) activity or the same role in protecting against cardiovascular risk factors and thrombosis. This study was undertaken to address the frequency of HCQ retinopathy and the role of HCQ blood levels in identifying those individuals who are at a greater future risk of retinopathy.MethodsHCQ blood levels in 537 patients with SLE from a large clinical cohort were repeatedly measured, and patients were tested for HCQ retinopathy. We assessed the risk of retinopathy according to clinical characteristics and blood levels of HCQ.ResultsThe overall frequency of retinopathy was 4.3% (23 of 537 patients). There was a 1% risk of retinopathy in the first 5 years of HCQ treatment, 1.8% from 6 to 10 years, 3.3% from 11 to 15 years, 11.5% from 16 to 20 years, and 8.0% after 21 years of use. We found that older age (P < 0.0001), higher body mass index (P for trend = 0.0160), and longer duration of HCQ intake (P = 0.0024 and P for trend = 0.0006) were associated with a higher risk of HCQ toxicity. Higher blood levels of HCQ predicted later HCQ retinopathy (P = 0.0124 and P = 0.0340 for mean and maximum HCQ blood levels, respectively).ConclusionOur data prove the utility of assessing blood levels of HCQ in the prediction of retinopathy. This would allow clinicians to either decrease the dose or increase monitoring in those patients with high HCQ blood levels.
Annals of the rheumatic diseases · 2017
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Annals of the rheumatic diseases · 2026 · Journal Article
Assawasaksakul T, Fava A, Goldman D, Magder LS, et al.
Arthritis care & research · 2025 · Journal Article
Madanchi N, Fava A, Goldman DW, Magder LS, et al.
Arthritis care & research · 2025 · Journal Article
Madanchi N, Fava A, Goldman DW, Magder LS, et al.
Lupus science & medicine · 2024 · Journal Article
Hunnicutt J, Georgiou ME, Richards A, Quasny H, et al.
Lupus science & medicine · 2023 · Journal Article
Magder LS, Fava A, Goldman D, Petri MA
Arthritis care & research · 2023 · Journal Article
Petri M, Joyce D, Haag K, Fava A, et al.
The Journal of rheumatology · 2022 · Journal Article
Kallas R, Li J, Goldman DW, Magder LS, et al.
Lupus · 2022 · Journal Article
Connolly CM, Li J, Goldman D, Fava A, et al.
Arthritis care & research · 2021 · Comparative Study
Petri M, Goldman DW, Alarcón GS, Gordon C, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Demir S, Li J, Magder LS, Petri M
The Journal of rheumatology · 2021 · Journal Article
Petri M, Barr E, Magder LS
Lupus · 2021 · Journal Article
Yip TC, Saria S, Petri M, Magder LS
Lupus science & medicine · 2020 · Journal Article
Petri MA, Avci M, Magder LS
Lupus science & medicine · 2020 · Journal Article
Khawaja M, Magder L, Goldman D, Petri MA
The Journal of rheumatology · 2020 · Journal Article
Stojan G, Magder LS, Petri M
Lupus science & medicine · 2019 · Journal Article
Petri MA, Barr E, Magder LS
BMC medical genomics · 2019 · Journal Article
Petri M, Fu W, Ranger A, Allaire N, et al.
Lupus science & medicine · 2018 · Journal Article
Giannakou I, Chatzidionysiou K, Magder LS, Györi N, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2018 · Comparative Study
Petri M, Magder LS
Lupus science & medicine · 2018 · Journal Article
Davidson JE, Fu Q, Rao S, Magder LS, et al.
Lupus · 2018 · Journal Article
Ng X, dosReis S, Beardsley R, Magder L, et al.
Lupus · 2017 · Journal Article
Kiani AN, Aukrust P, Ueland T, Hollan I, et al.
Lupus science & medicine · 2017 · Journal Article
Duarte-García A, Barr E, Magder LS, Petri M
Annals of the rheumatic diseases · 2017 · Journal Article
Wilhelm TR, Magder LS, Petri M
Lupus science & medicine · 2017 · Journal Article
Györi N, Giannakou I, Chatzidionysiou K, Magder L, et al.
Rheumatology international · 2017 · Journal Article
Khan A, Arbab-Zadeh A, Kiani AN, Magder LS, et al.
Lupus science & medicine · 2016 · Journal Article
Domingues V, Magder LS, Petri M
The Journal of rheumatology · 2016 · Journal Article
Durcan L, Winegar DA, Connelly MA, Otvos JD, et al.
The Journal of rheumatology · 2016 · Journal Article
Huang X, Magder LS, Petri M
Arthritis care & research · 2026 · Journal Article
Zhang S, Magder L, Goldman D, James JA, et al.
Lupus science & medicine · 2025 · Journal Article
Malvica S, Fenaroli P, Lee CY, Louis S, et al.
bioRxiv : the preprint server for biology · 2024 · Journal Article
Malvica S, Fenaroli P, Lee CY, Louis S, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2024 · Journal Article
Fava A, Wagner CA, Guthridge CJ, Kheir J, et al.
Arthritis care & research · 2024 · Journal Article
Jacobson R, Goldman D, Fava A, Magder L, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2020 · Evaluation Study
Petri M, Elkhalifa M, Li J, Magder LS, et al.
The Journal of rheumatology · 2016 · Journal Article
Durcan L, Winegar DA, Connelly MA, Otvos JD, et al.
JAMA network open · 2025 · Journal Article
Kim YJ, Lovell J, Diab A, Magder LS, et al.
COPD · 2021 · Journal Article
Le TT, Qato DM, Magder L, Bjarnadóttir M, et al.
The Journal of arthroplasty · 2020 · Journal Article
Finch DJ, Pellegrini VD Jr, Franklin PD, Magder LS, et al.
The Journal of arthroplasty · 2020 · Journal Article
Finch DJ, Martin BI, Franklin PD, Magder LS, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Demir S, Li J, Magder LS, Petri M
Lupus science & medicine · 2020 · Journal Article
Khawaja M, Magder L, Goldman D, Petri MA
Lupus science & medicine · 2019 · Journal Article
Petri MA, Barr E, Magder LS
JCI insight · 2024 · Journal Article
Fava A, Buyon J, Magder L, Hodgin J, et al.
Lupus science & medicine · 2022 · Clinical Trial
Weeding E, Fava A, Mohan C, Magder L, et al.
Lupus science & medicine · 2022 · Journal Article
Weeding E, Fava A, Magder L, Goldman D, et al.
Lupus · 2021 · Journal Article
Elkhalifa M, Orbai AM, Magder LS, Petri M, et al.
JCI insight · 2020 · Journal Article
Fava A, Buyon J, Mohan C, Zhang T, et al.
Arthritis care & research · 2020 · Journal Article
Babaoğlu H, Li J, Goldman D, Magder LS, et al.
Lupus · 2019 · Journal Article
Babaoglu H, Li J, Goldman D, Magder LS, et al.
The Journal of rheumatology · 2018 · Journal Article
Davidson JE, Fu Q, Ji B, Rao S, et al.
Cureus · 2017 · Journal Article
Timlin H, Magder L, Petri M
Infection control and hospital epidemiology · 2016 · Journal Article
Jackson SS, Leekha S, Pineles L, Magder LS, et al.